Literature DB >> 28100617

Differences in Glycoprotein Complex Receptor Binding Site Accessibility Prompt Poor Cross-Reactivity of Neutralizing Antibodies between Closely Related Arenaviruses.

Rachel B Brouillette1, Elisabeth K Phillips1, Natarajan Ayithan1, Wendy Maury2.   

Abstract

The glycoprotein complex (GPC) of arenaviruses, composed of stable signal peptide, GP1, and GP2, is the only antigen correlated with antibody-mediated neutralization. However, despite strong cross-reactivity of convalescent antisera between related arenavirus species, weak or no cross-neutralization occurs. Two closely related clade B viruses, Machupo virus (MACV) and Junín virus (JUNV), have nearly identical overall GPC architecture and share a host receptor, transferrin receptor 1 (TfR1). Given structural and functional similarities of the GP1 receptor binding site (RBS) of these viruses and the recent demonstration that the RBS is an important target for neutralizing antibodies, it is not clear how these viruses avoid cross-neutralization. To address this, MACV/JUNV chimeric GPCs were assessed for interaction with a group of α-JUNV GPC monoclonal antibodies (MAbs) and mouse antisera against JUNV or MACV GPC. All six MAbs targeted GP1, with those that neutralized JUNV GPC-pseudovirions competing with each other for RBS binding. However, these MAbs were unable to bind to a chimeric GPC composed of JUNV GP1 containing a small disulfide bonded loop (loop 10) unique to MACV GPC, suggesting that this loop may block MAbs interaction with the GP1 RBS. Consistent with this loop causing interference, mouse anti-JUNV GPC antisera that solely neutralized pseudovirions bearing autologous GP1 provided enhanced neutralization of MACV GPC when this loop was removed. Our studies provide evidence that loop 10, which is unique to MACV GP1, is an important impediment to binding of neutralizing antibodies and contributes to the poor cross-neutralization of α-JUNV antisera against MACV.IMPORTANCE Multiple New World arenaviruses can cause severe disease in humans, and some geographic overlap exists among these viruses. A vaccine that protects against a broad range of New World arenaviruses is desirable for purposes of simplicity, cost, and broad protection against multiple National Institute of Allergy and Infectious Disease-assigned category A priority pathogens. In this study, we sought to better understand how closely related arenaviruses elude cross-species neutralization by investigating the structural bases of antibody binding and avoidance. In our studies, we found that neutralizing antibodies against two New World arenaviruses, Machupo virus (MACV) and Junín virus (JUNV), bound to the envelope glycoprotein 1 (GP1) with JUNV monoclonal antibodies targeting the receptor binding site (RBS). We further show that altered structures surrounding the RBS pocket in MACV GP1 impede access of JUNV-elicited antibodies.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  GPC; Junín virus; Machupo virus; New World arenavirus; arenavirus; clade B viruses; glycoprotein; neutralizing antibodies

Mesh:

Substances:

Year:  2017        PMID: 28100617      PMCID: PMC5355595          DOI: 10.1128/JVI.01454-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor.

Authors:  Zhaochun Chen; Elizabeth R Fischer; Diana Kouiavskaia; Bryan T Hansen; Steven J Ludtke; Bella Bidzhieva; Michelle Makiya; Liane Agulto; Robert H Purcell; Konstantin Chumakov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

2.  Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins.

Authors:  Vanessa K Martin; Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Paula M Cannon
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

3.  Past, present, and future of arenavirus taxonomy.

Authors:  Sheli R Radoshitzky; Yīmíng Bào; Michael J Buchmeier; Rémi N Charrel; Anna N Clawson; Christopher S Clegg; Joseph L DeRisi; Sébastien Emonet; Jean-Paul Gonzalez; Jens H Kuhn; Igor S Lukashevich; Clarence J Peters; Victor Romanowski; Maria S Salvato; Mark D Stenglein; Juan Carlos de la Torre
Journal:  Arch Virol       Date:  2015-07       Impact factor: 2.574

4.  Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses.

Authors:  M J Buchmeier; H A Lewicki; O Tomori; M B Oldstone
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

5.  Biological properties of Junin virus proteins. I. Identification of the immunogenic glycoprotein.

Authors:  B Cresta; P Padula; M de Martinez Segovia
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

6.  Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus.

Authors:  S M Buckley; J Casals
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

7.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 8.  Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Authors:  Melissa M Coughlin; Bellur S Prabhakar
Journal:  Rev Med Virol       Date:  2011-09-08       Impact factor: 6.989

9.  Arenaviruses.

Authors:  J Casals
Journal:  Yale J Biol Med       Date:  1975-05

10.  A SOLUBLE ANTIGEN OF LYMPHOCYTIC CHORIOMENINGITIS : II. INDEPENDENCE OF ANTI-SOLUBLE SUBSTANCE ANTIBODIES AND NEUTRALIZING ANTIBODIES, AND THE ROLE OF SOLUBLE ANTIGEN AND INACTIVE VIRUS IN IMMUNITY TO INFECTION.

Authors:  J E Smadel; M J Wall
Journal:  J Exp Med       Date:  1940-09-30       Impact factor: 14.307

View more
  10 in total

1.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

2.  Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein.

Authors:  Fatima Amanat; James Duehr; Cheng Huang; Slobodan Paessler; Gene S Tan; Florian Krammer
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

3.  Machupo Virus with Mutations in the Transmembrane Domain and Glycosylation Sites of the Glycoprotein Is Attenuated and Immunogenic in Animal Models of Bolivian Hemorrhagic Fever.

Authors:  Emily K Mantlo; Junki Maruyama; John T Manning; Timothy G Wanninger; Cheng Huang; Jeanon N Smith; Michael Patterson; Slobodan Paessler; Takaaki Koma
Journal:  J Virol       Date:  2022-03-28       Impact factor: 6.549

4.  Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

Authors:  Dylan M Johnson; Jenny D Jokinen; Min Wang; Tia Pfeffer; Irina Tretyakova; Ricardo Carrion; Anthony Griffiths; Peter Pushko; Igor S Lukashevich
Journal:  Vaccine       Date:  2020-02-25       Impact factor: 3.641

5.  Structure of the Lassa virus glycan shield provides a model for immunological resistance.

Authors:  Yasunori Watanabe; Jayna Raghwani; Joel D Allen; Gemma E Seabright; Sai Li; Felipe Moser; Juha T Huiskonen; Thomas Strecker; Thomas A Bowden; Max Crispin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

6.  Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies.

Authors:  Weng M Ng; Mehmet Sahin; Stefanie A Krumm; Jeffrey Seow; Antra Zeltina; Karl Harlos; Guido C Paesen; Daniel D Pinschewer; Katie J Doores; Thomas A Bowden
Journal:  mBio       Date:  2022-03-22       Impact factor: 7.786

7.  Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.

Authors:  Antra Zeltina; Stefanie A Krumm; Mehmet Sahin; Weston B Struwe; Karl Harlos; Jack H Nunberg; Max Crispin; Daniel D Pinschewer; Katie J Doores; Thomas A Bowden
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

8.  Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses.

Authors:  Lars E Clark; Selma Mahmutovic; Donald D Raymond; Taleen Dilanyan; Takaaki Koma; John T Manning; Sundaresh Shankar; Silvana C Levis; Ana M Briggiler; Delia A Enria; Kai W Wucherpfennig; Slobodan Paessler; Jonathan Abraham
Journal:  Nat Commun       Date:  2018-05-14       Impact factor: 14.919

9.  Distinct Roles for Sialoside and Protein Receptors in Coronavirus Infection.

Authors:  Enya Qing; Michael Hantak; Stanley Perlman; Tom Gallagher
Journal:  mBio       Date:  2020-02-11       Impact factor: 7.867

10.  Rational design of universal immunotherapy for TfR1-tropic arenaviruses.

Authors:  Hadas Cohen-Dvashi; Ron Amon; Krystle N Agans; Robert W Cross; Aliza Borenstein-Katz; Mathieu Mateo; Sylvain Baize; Vered Padler-Karavani; Thomas W Geisbert; Ron Diskin
Journal:  Nat Commun       Date:  2020-01-03       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.